Dyshidrosis
diseaseOn this page
Also known as DYSHYDROTIC eczemavesicular eczema of hands and/or feet
Summary
Dyshidrosis (MONDO:0006540) is a disease with 6 GWAS associations across 5 studies. A subtype of sweat gland disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dyshidrosis |
| Mondo ID | MONDO:0006540 |
| EFO | EFO:1000688 |
| MeSH | D011146 |
| DOID | DOID:9230 |
| ICD-10-CM | L30.1 |
| SNOMED CT | 402567004 |
| UMLS | C0032633 |
| MedGen | 10851 |
| Is cancer (heuristic) | no |
Also known as: dyshidrosis · DYSHYDROTIC eczema · vesicular eczema of hands and/or feet
Data availability: 6 GWAS associations (5 studies).
Disease family
This is a subtype of sweat gland disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › sweat gland disorder › dyshidrosis
Related subtypes (5): sweat gland neoplasm, anhidrosis, Fox-Fordyce disease, miliaria, apocrine sweat gland disorder
Genetics & variants
GWAS landscape
6 GWAS associations across 5 studies. Top hits map to 4 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs187420997 | 8e-16 | LINC01924 - LINC01916 | C | 3.51 |
| rs183433223 | 1e-12 | TNIK | C | 3.01 |
| rs558850072 | 6e-12 | TCERG1L | G | 2.63 |
| rs571769378 | 2e-11 | DLG2 | C | 3.08 |
| rs183168537 | 4e-11 | PTPRD | C | 3.65 |
| rs144928521 | 2e-09 | ASS1P10 - PRELID2 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478832 | Verma A | 2024 | 1,549 | 446,736 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478831 | Verma A | 2024 | 633 | 120,286 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480477 | Verma A | 2024 | 633 | 120,286 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651325 | Liu TY | 2025 | 419 | 227,516 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90482362 | Verma A | 2024 | 273 | 59,198 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 6 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 5 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 5 |
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs187420997 | 18 | 64664207 | C>G,T | 0.001 | intergenic_variant | LINC01924 - LINC01916 | 8e-16 | Tier 4: intronic/intergenic |
| rs183433223 | 3 | 171283668 | C>T | 0 | intron_variant | TNIK | 1e-12 | Tier 4: intronic/intergenic |
| rs558850072 | 10 | 131208509 | G>A | 0 | intron_variant | TCERG1L | 6e-12 | Tier 4: intronic/intergenic |
| rs571769378 | 11 | 85548741 | C>T | 0 | intron_variant | DLG2 | 2e-11 | Tier 4: intronic/intergenic |
| rs183168537 | 9 | 9223745 | C>T | 0.001 | intron_variant | PTPRD | 4e-11 | Tier 4: intronic/intergenic |
| rs144928521 | 5 | 145359616 | A>G | intron_variant | ASS1P10 - PRELID2 | 2e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.